Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical and Economic Benefits Across Established BMI Strata in Patients with Type 2 Diabetes Including Those Overweight and Obese

November 12, 2018

BRIDGEWATER, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one,wearable insulin delivery option for patients with diabetes, announced today a poster titled “Relationship between Baseline BMI and Clinical Outcomes with V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes Previously Prescribed Basal-Bolus Regimens” was presented over the weekend at the 18th Annual Diabetes Technology Meeting in North Bethesda, Maryland.

Obesity has been associated with higher insulin requirements in patients with type 2 diabetes, therefore evaluating the impact of body mass index (BMI), a measurement of body fat, on insulin treatment is important. V-Go wearable delivery device has demonstrated lower A1c levels with less insulin; however, the effect of BMI on insulin dose and change in A1c with V-Go has not been evaluated. This study investigated the impact to A1c and Total Daily Dose (TDD) in patients with type 2 diabetes who were switched from prior insulin regimens to V-Go when findings were stratified by established BMI strata (normal-weight, overweight, obesity class I, II or III). Clinical outcomes across all five BMI strata were evaluated after a mean of three months of V-Go use. The findings demonstrated all strata benefited from a reduction in A1c (range of -0.7% to 1.5%) and reduction in TDD (range of -17 units per day to -38 units per day) compared to baseline.

“We are excited by the findings of this study,” said John Timberlake, President and Chief Executive Officer of Valeritas. “We have taken our growing portfolio of positive clinical data a step further, demonstrating the use of V-Go can clinically benefit patients with type 2 diabetes across all BMI strata.”

About Valeritas Holdings, Inc.

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.

More information is available at www.valeritas.com and our Twitter feed at www.twitter.com/Valeritas_US.

Forward-Looking Statements

This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at http://www.sec.gov.

Investor Contacts:Lynn Pieper Lewis or Greg ChodaczekGilmartin Group646-924-1769 ir@valeritas.com

Media Contact:Kevin KnightKnight Marketing Communications, Ltd.(206) 451-4823 pr@valeritas.com

Update hourly